Major Estimate Revision • May 19
Consensus revenue estimates fall by 80% The consensus outlook for revenues in fiscal year 2026 has deteriorated. 2026 revenue forecast decreased from US$8.54m to US$1.75m. Forecast losses increased from -US$1.15 to -US$1.59 per share. Biotechs industry in the US expected to see average net income decline 9.8% next year. Consensus price target of US$14.00 unchanged from last update. Share price fell 14% to US$0.48 over the past week. New Risk • May 17
New minor risk - Profitability The company is currently unprofitable and not forecast to become profitable over the next 3 years. Trailing 12-month net loss: US$21m Forecast net loss in 3 years: US$20m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$27m free cash flow). Shareholders have been substantially diluted in the past year (281% increase in shares outstanding). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$20m net loss in 3 years). Share price has been volatile over the past 3 months (13% average weekly change). Market cap is less than US$100m (US$19.6m market cap). New Risk • May 14
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -US$27m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$27m free cash flow). Shareholders have been substantially diluted in the past year (281% increase in shares outstanding). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$13m net loss in 3 years). Share price has been volatile over the past 3 months (13% average weekly change). Market cap is less than US$100m (US$20.0m market cap). Reported Earnings • May 14
First quarter 2026 earnings released: US$1.25 loss per share (vs US$1.25 loss in 1Q 2025) First quarter 2026 results: US$1.25 loss per share (in line with 1Q 2025). Net loss: US$24.2m (loss widened 128% from 1Q 2025). Revenue is forecast to grow 48% p.a. on average during the next 3 years, compared to a 22% growth forecast for the Biotechs industry in the US. Tillkännagivande • May 06
Curis, Inc. to Report Q1, 2026 Results on May 12, 2026 Curis, Inc. announced that they will report Q1, 2026 results at 4:00 PM, US Eastern Standard Time on May 12, 2026 Tillkännagivande • May 02
Curis, Inc. Receives Notice of Nasdaq Delisting Due to Bid Price Non-Compliance As previously disclosed, on February 3, 2026, Curis, Inc. (the “Company”) became subject to a Discretionary Panel Monitor for a period of one-year pursuant to Listing Rule 5815(d)(4)(A). If, within the one-year monitoring period, the Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market (“Nasdaq”) finds the Company again out of compliance with any of Nasdaq’s Listing Rules, notwithstanding Rule 5810(c)(2), the Company will not be permitted to provide the Staff with a plan of compliance with respect to that deficiency, and the Staff will not be permitted to grant additional time for the Company to regain compliance with respect to that deficiency, nor will the Company be afforded an applicable cure or compliance period pursuant to Rule 5810(c)(3). Instead, the Staff will issue a Delist Determination Letter, and the Company will have an opportunity to request a new hearing with the initial Nasdaq Hearings Panel (“Panel”) or a newly convened Panel if the initial Panel is unavailable. The Company will have the opportunity to respond/present to the Panel as provided by Listing Rule 5815(d)(4)(C).
On April 27, 2026, the Company received a Delist Determination Letter from the Staff notifying the Company that, for the last 30 consecutive business days, the bid price for the Company’s common stock had closed below the minimum $1.00 per share requirement for continued inclusion on the Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Rule”), and the Company’s securities will be scheduled for delisting from the Nasdaq Capital Market and suspended at the opening of trading on May 6, 2026 unless the Company timely appeals the Staff’s delisting determination by requesting a hearing before the Panel by May 4, 2026. The Company intends to make a timely request for a new hearing with the initial Panel or a newly convened Panel if the initial Panel is unavailable, which will stay any further delisting actions. However, there can be no assurance that such appeal will be successful or that the Company will remain listed on Nasdaq. Tillkännagivande • Apr 13
Curis, Inc., Annual General Meeting, May 19, 2026 Curis, Inc., Annual General Meeting, May 19, 2026. Major Estimate Revision • Mar 26
Consensus revenue estimates decrease by 32%, EPS upgraded The consensus outlook for fiscal year 2026 has been updated. 2026 revenue forecast fell from US$12.5m to US$8.54m. EPS estimate increased from -US$1.73 to -US$1.11 per share. Biotechs industry in the US expected to see average net income decline 12% next year. Consensus price target of US$14.00 unchanged from last update. Share price fell 23% to US$0.58 over the past week. New Risk • Mar 25
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: US$9.82m This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Shareholders have been substantially diluted in the past year (62% increase in shares outstanding). Market cap is less than US$10m (US$9.82m market cap). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$28m net loss in 3 years). Share price has been volatile over the past 3 months (11% average weekly change). Reported Earnings • Mar 20
Full year 2025 earnings: EPS exceeds analyst expectations while revenues lag behind Full year 2025 results: US$0.58 loss per share (improved from US$6.88 loss in FY 2024). Revenue: US$9.44m (down 13% from FY 2024). Net loss: US$7.58m (loss narrowed 83% from FY 2024). Revenue missed analyst estimates by 18%. Earnings per share (EPS) exceeded analyst estimates by 77%. Revenue is forecast to grow 44% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, earnings per share has increased by 43% per year but the company’s share price has fallen by 59% per year, which means it is significantly lagging earnings. Tillkännagivande • Mar 13
Curis, Inc. to Report Q4, 2025 Results on Mar 19, 2026 Curis, Inc. announced that they will report Q4, 2025 results at 4:00 PM, US Eastern Standard Time on Mar 19, 2026 Tillkännagivande • Feb 10
Curis, Inc. Receives Written Notice from the Nasdaq Stock Market On February 3, 2026, Curis, Inc. received written notice from the Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company has regained compliance with Nasdaq Listing Rule 5550(b)(2) (“MVLS Rule”) and is in full compliance with the terms set forth by the Nasdaq Hearings Panel (the “Panel”). Pursuant to Listing Rule 5815(d)(4)(A), the Company will be subject to a Discretionary Panel Monitor for a period of one-year. If, within the one-year monitoring period, the Listing Qualifications Department (“Staff”) finds the Company again out of compliance with any of Nasdaq’s Listing Rules, notwithstanding Rule 5810(c)(2), the Company will not be permitted to provide the Staff with a plan of compliance with respect to that deficiency and the Staff will not be permitted to grant additional time for the Company to regain compliance with respect to that deficiency, nor will the Company be afforded an applicable cure or compliance period pursuant to Rule 5810(c)(3). Instead, the Staff will issue a Delist Determination Letter and the Company will have an opportunity to request a new hearing with the initial Panel or a newly convened Hearings Panel if the initial Panel is unavailable. The Company will have the opportunity to respond/present to the Hearings Panel as provided by Listing Rule 5815(d)(4)(C). The Company’s securities may be at that time delisted from Nasdaq. Tillkännagivande • Jan 09
Curis, Inc. announced that it has received $20.195 million in funding On January 9, 2026, Curis, Inc. closed the transaction. Tillkännagivande • Jan 08
Curis, Inc. announced that it expects to receive $20.195 million in funding Curis, Inc. announced that it has entered into a securities purchase agreement with new and existing healthcare-focused, high-quality institutional investors and certain insiders of the company for a private placement to issue 20,195 shares of series B convertible non-redeemable preferred stock at an issue price of $1,000 for gross proceeds of $20,195,000, series A warrants to purchase 26,926,675 shares of the common stock or in certain circumstances pre-funded warrants, series B warrants to purchase 26,926,675 shares of common stock or in certain circumstances pre-funded warrants and series C warrants to purchase 26,926,675 shares of common stock or in certain circumstances pre-funded warrants for aggregate proceeds of $20,195,000 on January 7, 2026. The transaction includes participation from company’s chief executive officer, chief financial officer, chief medical officer, chief development officer and a member of the board of directors. Each share of series B preferred stock is being sold together with a series A warrant to purchase 1,333.33 shares of common stock, a series B warrant to purchase 1,333.33 shares of common stock and a series C warrant to purchase 1,333.33 shares of common stock. The warrants will each have an exercise price of $0.75 per share. The conversion price will be of $0.75. The closing of the PIPE financing is subject to the satisfaction of customary closing conditions and is expected to occur on or about January 8, 2026. The series A warrants will be exercisable following receipt of requisite stockholder approval and the certificate of amendment filing and will terminate on January 8, 2031. The series B warrants will be exercisable following the receipt of requisite stockholder approval and the certificate of amendment filing and will terminate upon the 30th calendar day following date on which the company publicly announces that the fifth patient has been dosed in the company’s phase 2 clinical trial of emavusertib in combination with an approved Bruton Tyrosine Kinase Inhibitor in chronic lymphocytic leukemia. The series C warrants will be exercisable following the receipt of requisite stockholder approval and the certificate of amendment filing and will terminate on July 8, 2027. The company has agreed to pay customary placement fees and reimburse certain expenses of the placement agent. Tillkännagivande • Dec 09
Curis, Inc. Provides Updated Data from its Frontline AML Triplet Study Curis, Inc. provided updated clinical data from the ongoing frontline Acute Myeloid Leukemia (AML) triplet study (CA-4948-104) in a poster presentation at the 67th ASH Annual Meeting (ASH). The AML triplet study is evaluating the addition of emavusertib (ema) to the combination of venetoclax and azacitidine (ven-aza) in AML patients who have achieved complete remission on ven-aza but remain MRD-positive (MRD+), with the goal of enabling patients to achieve uMRD. In the ASH abstract, the company reported initial data showing 4 of 8 patients (50%) had achieved uMRD as of July 2, 2025. These data were updated in the poster presented at ASH with 5 of 8 patients (62.5%) achieving uMRD, with no change in safety profile, as of October 12, 2025. New Risk • Dec 04
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$30m free cash flow). Negative equity (-US$15m). Shareholders have been substantially diluted in the past year (53% increase in shares outstanding). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$29m net loss in 3 years). Share price has been volatile over the past 3 months (11% average weekly change). Market cap is less than US$100m (US$16.2m market cap). New Risk • Nov 09
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -US$30m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$30m free cash flow). Negative equity (-US$15m). Shareholders have been substantially diluted in the past year (49% increase in shares outstanding). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$32m net loss in 3 years). Market cap is less than US$100m (US$16.4m market cap). Board Change • Nov 02
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 9 experienced directors. 3 highly experienced directors. Independent Director Anne Borgman-Hagey was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Tillkännagivande • Oct 31
Curis, Inc. to Report Q3, 2025 Results on Nov 06, 2025 Curis, Inc. announced that they will report Q3, 2025 results at 4:00 PM, US Eastern Standard Time on Nov 06, 2025 Tillkännagivande • Oct 25
Nasdaq Grants Exception Period to Curis, Inc. to Regain Compliance As previously disclosed, on August 21, 2025, Curis, Inc. (the Company") received notice from the Listing Qualifications Department (the Staff") of the Nasdaq Stock Market LLC (Nasdaq") stating that, because the Company has not regained compliance with Nasdaq Listing Rule 5550(b)(2) (the MVLS Requirement") which requires the market value of the Company's listed securities to be at least $35,000,000, its securities would be delisted from The Nasdaq Capital Market unless the Company timely appeals the Staff's delisting determination by requesting a hearing before the Nasdaq Hearings Panel (the Panel") by August 28, 2025. The Company timely requested a hearing before the Panel, which request stayed any further suspension or delisting action by the Staff, pending the ultimate conclusion of the hearing process. On October 20, 2025, the Company received written notice from Nasdaq indicating that the Panel has granted the Company an exception until November 14, 2025 (Exception Period") to regain compliance with the MVLS Requirement. During the Exception Period, the Company is required to provide prompt notification of any significant events that occur during this period that may affect the Company's compliance with Nasdaq requirements including any event that may call into question the Company's ability to meet the terms of the exception granted. The Panel reserves the right to reconsider the terms of this exception based on any event, condition or circumstance that exists or develops that would, in the opinion of the Panel, make continued listing of the Company's securities on Nasdaq inadvisable or unwarranted. There can be no assurance that the Company will ultimately regain compliance and remain listed on Nasdaq. Tillkännagivande • Aug 23
Curis, Inc. Receives Notice from Nasdaq Due to MVLS Requirement Non-Compliance As previously disclosed, on February 21, 2025, Curis, Inc. received notice from the Listing Qualifications Department of the Nasdaq Stock Market LLC that the Company was not in compliance with Nasdaq Listing Rule 5550(b)(2) (the “MVLS Requirement”), as the market value of the Company’s listed securities had been below $35,000,000 for the previous 30 consecutive trading days. Nasdaq provided the Company with a compliance period of 180 calendar days, or until August 20, 2025 (the “Compliance Period”), to regain compliance with the MVLS Requirement. On August 21, 2025, the Company received notice from the Staff stating that, because the Company has not regained compliance with the MVLS Requirement, its securities would be delisted from The Nasdaq Capital Market unless the Company timely appeals the Staff’s delisting determination by requesting a hearing before the Nasdaq Hearings Panel (the “Panel”) by August 28, 2025. The Company intends to make a timely request for a hearing before the Panel to appeal the Staff’s determination. The Company’s request for a hearing will stay the suspension and delisting of the Company’s securities by the Staff pending the ultimate outcome of the hearing. The Company’s common stock will remain listed and eligible for trading on Nasdaq pending the Panel’s decision; however, there can be no assurance that the Company will ultimately regain compliance and remain listed on Nasdaq. Major Estimate Revision • Aug 12
Consensus estimates of losses per share improve by 31% The consensus outlook for earnings per share (EPS) in fiscal year 2025 has improved. 2025 revenue forecast increased from US$10.7m to US$11.0m. EPS estimate increased from -US$3.76 per share to -US$2.61 per share. Biotechs industry in the US expected to see average net income decline 12% next year. Consensus price target of US$16.33 unchanged from last update. Share price was steady at US$1.65 over the past week. New Risk • Aug 08
New major risk - Revenue and earnings growth Earnings are forecast to decline by an average of 7.2% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Negative equity (-US$14m). Earnings are forecast to decline by an average of 7.2% per year for the foreseeable future. Shareholders have been substantially diluted in the past year (109% increase in shares outstanding). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$57m net loss in 3 years). Share price has been volatile over the past 3 months (11% average weekly change). Market cap is less than US$100m (US$21.4m market cap). Reported Earnings • Aug 05
Second quarter 2025 earnings: EPS and revenues exceed analyst expectations Second quarter 2025 results: US$0.68 loss per share (improved from US$2.03 loss in 2Q 2024). Revenue: US$2.75m (up 8.0% from 2Q 2024). Net loss: US$8.59m (loss narrowed 27% from 2Q 2024). Revenue exceeded analyst estimates by 4.2%. Earnings per share (EPS) also surpassed analyst estimates by 50%. Revenue is forecast to grow 44% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, earnings per share has increased by 28% per year but the company’s share price has fallen by 56% per year, which means it is significantly lagging earnings. Tillkännagivande • Jul 29
Curis, Inc. to Report Q2, 2025 Results on Aug 05, 2025 Curis, Inc. announced that they will report Q2, 2025 results at 8:00 AM, US Eastern Standard Time on Aug 05, 2025 Tillkännagivande • Jul 02
Curis, Inc. has filed a Follow-on Equity Offering in the amount of $3.499997 million. Curis, Inc. has filed a Follow-on Equity Offering in the amount of $3.499997 million.
Security Name: Common Stock
Security Type: Common Stock
Securities Offered: 1,538,460
Price\Range: $2.275
Discount Per Security: $0.159
Transaction Features: Registered Direct Offering Reported Earnings • May 07
First quarter 2025 earnings: EPS and revenues miss analyst expectations First quarter 2025 results: US$1.25 loss per share (improved from US$2.05 loss in 1Q 2024). Revenue: US$2.38m (up 14% from 1Q 2024). Net loss: US$10.6m (loss narrowed 11% from 1Q 2024). Revenue missed analyst estimates by 8.3%. Earnings per share (EPS) also missed analyst estimates by 5.3%. Revenue is forecast to grow 40% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, earnings per share has increased by 22% per year but the company’s share price has fallen by 51% per year, which means it is significantly lagging earnings. Tillkännagivande • Apr 29
Curis, Inc. to Report Q1, 2025 Results on May 06, 2025 Curis, Inc. announced that they will report Q1, 2025 results at 8:00 AM, US Eastern Standard Time on May 06, 2025 New Risk • Apr 08
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: US$9.85m This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Negative equity (-US$6.0m). Shareholders have been substantially diluted in the past year (44% increase in shares outstanding). Market cap is less than US$10m (US$9.85m market cap). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$44m net loss in 3 years). Share price has been volatile over the past 3 months (12% average weekly change). Major Estimate Revision • Apr 04
Consensus revenue estimates increase by 28% The consensus outlook for revenues in fiscal year 2025 has improved. 2025 revenue forecast increased from US$8.51m to US$10.9m. Forecast losses expected to reduce from -US$4.19 to -US$3.17 per share. Biotechs industry in the US expected to see average net income decline 13% next year. Consensus price target down from US$21.00 to US$18.50. Share price fell 47% to US$1.23 over the past week. Tillkännagivande • Apr 03
Curis, Inc., Annual General Meeting, May 20, 2025 Curis, Inc., Annual General Meeting, May 20, 2025. Price Target Changed • Mar 31
Price target decreased by 11% to US$20.00 Down from US$22.50, the current price target is an average from 4 analysts. New target price is 852% above last closing price of US$2.10. Stock is down 83% over the past year. The company is forecast to post a net loss per share of US$3.23 next year compared to a net loss per share of US$6.88 last year. Reported Earnings • Mar 30
Full year 2024 earnings: EPS in line with analyst expectations despite revenue beat Full year 2024 results: US$6.88 loss per share (improved from US$8.96 loss in FY 2023). Revenue: US$10.9m (up 8.8% from FY 2023). Net loss: US$43.4m (loss narrowed 8.5% from FY 2023). Revenue exceeded analyst estimates by 12%. Earnings per share (EPS) were mostly in line with analyst estimates. Revenue is forecast to grow 40% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Biotechs industry in the US. Tillkännagivande • Mar 29
Curis, Inc. to Report Q4, 2024 Results on Mar 31, 2025 Curis, Inc. announced that they will report Q4, 2024 results at 8:00 AM, US Eastern Standard Time on Mar 31, 2025 Tillkännagivande • Mar 28
Curis, Inc. has filed a Follow-on Equity Offering in the amount of $4.758381 million. Curis, Inc. has filed a Follow-on Equity Offering in the amount of $4.758381 million.
Security Name: Common Stock
Security Type: Common Stock
Securities Offered: 1,974,432
Price\Range: $2.41
Security Name: Pre-funded Warrants
Security Type: Equity Warrant
Securities Offered: 2,184,009
Transaction Features: Registered Direct Offering Tillkännagivande • Feb 28
Curis Receives Non-Compliance Notice from Nasdaq Regarding MVLS Requirement On February 21, 2025, Curis, Inc. received notice (the Notice") from the Listing Qualifications Department of the Nasdaq Stock Market LLC (Nasdaq") that the Company was not in compliance with Nasdaq Listing Rule 5550(b)(2) (the MVLS Requirement"), as the market value of the Company's listed securities had been below $35,000,000 for the last 30 consecutive business days. The Notice indicated that Nasdaq Listing Rule 5810(c)(3)(C) provides the Company a compliance period of 180 calendar days, or until August 20, 2025 (the Compliance Period"), to regain compliance with the MVLS Requirement. In order to regain compliance, the market value of the Company's listed securities must close at $35,000,000 or more for a minimum of 10 consecutive business days. If the Company does not regain compliance within the Compliance Period, the Company will receive written notification that its securities are subject to delisting from the Nasdaq Capital Market. There can be no assurance that the Company will be able to regain compliance with the MVLS Requirement or otherwise maintain compliance with Nasdaq's other listing requirements. New Risk • Jan 16
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 44% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Negative equity (-US$8.7m). Shareholders have been substantially diluted in the past year (44% increase in shares outstanding). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$52m net loss in 3 years). Share price has been volatile over the past 3 months (14% average weekly change). Market cap is less than US$100m (US$27.0m market cap). New Risk • Jan 02
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 14% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Negative equity (-US$8.7m). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$52m net loss in 3 years). Share price has been volatile over the past 3 months (14% average weekly change). Shareholders have been diluted in the past year (44% increase in shares outstanding). Market cap is less than US$100m (US$25.9m market cap). Tillkännagivande • Dec 10
Curis, Inc. Announces Additional Data from Take Aim Leukemia Study Curis, Inc. presented data from the Take Aim Leukemia study (CA-4948-102) in relapsed/refractory (R/R) Acute Myeloid Leukemia (AML) at the 66th ASH annual meeting. The additional data presented include data for 21 patients with a FLT3 mutation (FLT3m) who had received fewer than 3 lines of prior therapy and were treated with emavusertib as monotherapy at the Recommended Phase 2 Dose (RP2D) of 300 mg BID. This brings the total number of patients dosed at the RP2D from 12 to 21 patients. Emavusertib is currently undergoing testing in the Phase 1/2 Take Aim Lymphoma study (CA-4948 -101) in patients with relapsed/refractory primary central nervous system lymphoma (PCNSL) in combination with the BTK inhibitor ibrutinib, as a monotherapy in the Phase 1/2 take Aim Leukemia study (CA -4948-102) in patients with relapsed-refractory acute myeloid leukemia (AML) and relapsed/refractory high risk myelodysplastic syndrome (hrMDS) with either a FLT3 mutation or a splicing factor mutation (U2AF1 or SF3B2), and as a frontline combination therapy with azacitidine and venetoclax in patents with AML (CA-4948-104). Emavusertib has received Orphan Drug Designation from the U.S. Food and Drug Administration for the treatment of AML and MDS and from the European Commission for the treatment of PCNSL. Curis, through its 2015 collaboration with Aurigene, has the exclusive license to emavusertib (CA-4948). Reported Earnings • Nov 17
Third quarter 2024 earnings: EPS and revenues exceed analyst expectations Third quarter 2024 results: US$1.70 loss per share (improved from US$2.13 loss in 3Q 2023). Revenue: US$2.93m (up 3.5% from 3Q 2023). Net loss: US$10.1m (loss narrowed 17% from 3Q 2023). Revenue exceeded analyst estimates by 24%. Earnings per share (EPS) also surpassed analyst estimates by 9.1%. Revenue is forecast to grow 41% p.a. on average during the next 3 years, compared to a 22% growth forecast for the Biotechs industry in the US. Tillkännagivande • Nov 07
Curis, Inc. to Report Q3, 2024 Results on Nov 14, 2024 Curis, Inc. announced that they will report Q3, 2024 results at 8:00 AM, US Eastern Standard Time on Nov 14, 2024 New Risk • Nov 01
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 42% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Negative equity (-US$694k). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$54m net loss in 3 years). Share price has been volatile over the past 3 months (13% average weekly change). Shareholders have been diluted in the past year (42% increase in shares outstanding). Market cap is less than US$100m (US$35.9m market cap). Tillkännagivande • Oct 30
Curis, Inc. has filed a Follow-on Equity Offering in the amount of $12.099999 million. Curis, Inc. has filed a Follow-on Equity Offering in the amount of $12.099999 million.
Security Name: Common Shares
Security Type: Common Stock
Securities Offered: 2,398,414
Price\Range: $5.045
Discount Per Security: $0.389
Transaction Features: Registered Direct Offering Price Target Changed • Oct 22
Price target decreased by 9.1% to US$22.50 Down from US$24.75, the current price target is an average from 4 analysts. New target price is 313% above last closing price of US$5.45. Stock is up 39% over the past year. The company is forecast to post a net loss per share of US$7.07 next year compared to a net loss per share of US$8.96 last year. New Risk • Aug 21
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 13% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Negative equity (-US$694k). Minor Risks Less than 1 year of cash runway based on current free cash flow (-US$43m). Currently unprofitable and not forecast to become profitable over next 3 years (US$49m net loss in 3 years). Share price has been volatile over the past 3 months (13% average weekly change). Market cap is less than US$100m (US$26.3m market cap). New Risk • Aug 02
New major risk - Negative shareholders equity The company has negative equity. Total equity: -US$694k This is considered a major risk. Being in negative equity means that the company's liabilities exceed its assets, meaning it owes more to creditors than it has in owned assets. While this doesn't mean the company is about to collapse, in the long-term, this is unsustainable. The company may have issues meeting financial obligations, is at risk of becoming insolvent and may have difficulty raising capital, especially more debt, if needed. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$43m free cash flow). Negative equity (-US$694k). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$54m net loss in 3 years). Market cap is less than US$100m (US$29.1m market cap). Reported Earnings • Aug 02
Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind Second quarter 2024 results: US$2.03 loss per share (improved from US$2.47 loss in 2Q 2023). Revenue: US$2.55m (up 16% from 2Q 2023). Net loss: US$11.8m (loss narrowed 1.3% from 2Q 2023). Revenue exceeded analyst estimates by 23%. Earnings per share (EPS) missed analyst estimates by 21%. Revenue is forecast to grow 41% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Biotechs industry in the US. Major Estimate Revision • Aug 02
Consensus revenue estimates increase by 14% The consensus outlook for fiscal year 2024 has been updated. 2024 revenue forecast increased from US$8.78m to US$10.0m. EPS estimate unchanged from -US$5.49 at last update. Biotechs industry in the US expected to see average net income decline 9.9% next year. Consensus price target of US$78.00 unchanged from last update. Share price fell 18% to US$4.94 over the past week. Tillkännagivande • Jul 25
Curis, Inc. to Report Q2, 2024 Results on Aug 01, 2024 Curis, Inc. announced that they will report Q2, 2024 results at 8:00 AM, US Eastern Standard Time on Aug 01, 2024 Tillkännagivande • May 16
Curis, Inc. Announces Additional Data from Take Aim Leukemia Study Curis, Inc. announced updated data from the ongoing TakeAim Leukemia study (CA-4948-102) in relapsed/refractory (R/R) AML to be presented at the ASCO and EHA conferences. This update includes data for 25 new patients in the FLT3 mutation (FLT3m) and U2AF1/SF3B1 Splicing Factor mutation (SFm) cohorts who had received fewer than 3 lines of prior therapy and were treated with emavusertib as monotherapy at the Recommended Phase 2 Dose (RP2D) of 300 mg BID. FLT3m Cohort – 12 relapsed/refractory patients enrolled to date: 12 R/R AML patients with FLT3m were treated with emavusertib. Prior therapies included venetoclax (8/12), hypomethylating agents or HMA (9/12), and FLT3 inhibitors (9/12). Preliminary data show 6 objective responses in 11 response-evaluable patients: 3 complete remission (CR), 1 CR with partial hematologic recovery (CRh) and 2 morphologic leukemia-free state (MLFS) with on-treatment duration range of 46-324 days. 4 patients are ongoing at the data-cutoff, including 1 CRh and 1 MLFS. 3 of 3 patients who were naïve to FLT3i treatment achieved objective response (2 CR, 1 MLFS). 3 of 8 patients who progressed on, or following, prior FLT3i treatment achieved objective response (1 CR, 1 CRh, 1 MLFS). 1 patient is not response-evaluable. All responders demonstrated complete normalization of blast counts in the bone marrow. One of these patients proceeded to allogenic stem cell transplantation. Responses were achieved rapidly in this population, with 5 of 6 responses occurring within one cycle of treatment. SFm Cohort – 20 relapsed/refractory patients enrolled to date: 20 R/R AML patients with SFm were treated with emavusertib. Prior therapies included venetoclax (18/20) and HMA (17/20). Preliminary data show 4 of 18 response-evaluable patients in this population have achieved objective response (CR/CRh/MLFS). 8 of 20 patients are ongoing at the data-cutoff, including 1 MLFS and 3 non-responding patients who have shown increased neutrophil counts. All 4 responders (1 CR, 2 CRh, 1 MLFS) had received prior treatment with an HMA; 3 of whom had also received prior treatment with venetoclax. 3 additional non-responding patients are ongoing and have shown increased neutrophil counts. 2 patients are not response-evaluable. All responders demonstrated complete normalization of blast counts in the bone marrow. One of these patients proceeded to allogenic stem cell transplantation. Reported Earnings • May 08
First quarter 2024 earnings: EPS in line with analyst expectations despite revenue beat First quarter 2024 results: US$2.05 loss per share. Revenue: US$2.09m (down 9.2% from 1Q 2023). Net loss: US$11.9m (loss widened 2.7% from 1Q 2023). Revenue is forecast to grow 37% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Biotechs industry in the US. Tillkännagivande • May 01
Curis, Inc. to Report Q1, 2024 Results on May 07, 2024 Curis, Inc. announced that they will report Q1, 2024 results at 8:00 AM, US Eastern Standard Time on May 07, 2024 Price Target Changed • Apr 28
Price target decreased by 22% to US$77.40 Down from US$99.25, the current price target is an average from 5 analysts. New target price is 435% above last closing price of US$14.47. Stock is down 16% over the past year. The company is forecast to post a net loss per share of US$6.21 next year compared to a net loss per share of US$8.96 last year. Tillkännagivande • Apr 11
Curis, Inc., Annual General Meeting, May 21, 2024 Curis, Inc., Annual General Meeting, May 21, 2024, at 10:00 US Eastern Standard Time. Agenda: To elect two Class I directors for a term of three years; to approve an advisory vote on executive compensation; to ratify the appointment of PricewaterhouseCoopers LLP as independent registered public accounting firm for the fiscal year ending December 31, 2024; to approve the fifth amended and restated 2010 Stock Incentive Plan to reserve up to an additional 942,100 shares of common stock for issuance under the plan and to provide for certain other amendments; to approve Amendment No. 2 to the amended and restated 2010 employee stock purchase plan; to adopt and approve an amendment to Restated Certificate of Incorporation, as amended, to provide for officer exculpation and to transact any other business that may properly come before the meeting or any adjournment thereof. Major Estimate Revision • Mar 08
Consensus EPS estimates upgraded to US$6.06 loss The consensus outlook for fiscal year 2024 has been updated. 2024 losses forecast to reduce from -US$6.73 to -US$6.06 per share. Revenue forecast unchanged from US$8.35m at last update. Biotechs industry in the US expected to see average net income decline 8.5% next year. Consensus price target of US$93.00 unchanged from last update. Share price rose 4.3% to US$10.50 over the past week. New Risk • Mar 08
New major risk - Revenue and earnings growth Earnings are forecast to decline by an average of 3.5% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 3.5% per year for the foreseeable future. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$64m net loss in 3 years). Share price has been volatile over the past 3 months (14% average weekly change). Shareholders have been diluted in the past year (22% increase in shares outstanding). Market cap is less than US$100m (US$58.8m market cap). Major Estimate Revision • Feb 15
Consensus revenue estimates increase by 28%, EPS downgraded The consensus outlook for fiscal year 2024 has been updated. 2024 revenue forecast increased from US$8.14m to US$10.4m. EPS estimate fell from -US$5.30 to -US$6.73 per share. Biotechs industry in the US expected to see average net income decline 8.5% next year. Consensus price target down from US$99.25 to US$93.00. Share price rose 9.6% to US$10.29 over the past week. Reported Earnings • Feb 10
Full year 2023 earnings: EPS and revenues miss analyst expectations Full year 2023 results: US$8.96 loss per share (improved from US$12.14 loss in FY 2022). Revenue: US$10.0m (down 1.4% from FY 2022). Net loss: US$47.4m (loss narrowed 16% from FY 2022). Revenue missed analyst estimates by 2.9%. Earnings per share (EPS) also missed analyst estimates by 31%. Revenue is forecast to grow 41% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Biotechs industry in the US. Tillkännagivande • Feb 09
Curis, Inc. has filed a Follow-on Equity Offering in the amount of $100 million. Curis, Inc. has filed a Follow-on Equity Offering in the amount of $100 million.
Security Name: Common Stock
Security Type: Common Stock
Transaction Features: At the Market Offering Tillkännagivande • Feb 02
Curis, Inc. to Report Q4, 2023 Results on Feb 08, 2024 Curis, Inc. announced that they will report Q4, 2023 results at 8:00 AM, US Eastern Standard Time on Feb 08, 2024 Tillkännagivande • Dec 12
Curis, Inc. Announces Initial Combination Study Data from Its Take Aim Lymphoma Study Curis, Inc. announced initial combination study data from its Take Aim Lymphoma trial including 5 primary CNS lymphoma (PCNSL) patients. As of October 12th, the Take Aim Lymphoma trial has enrolled and treated 19 Non-Hodgkin Lymphoma (NHL) patients, with a combination of emavusertib and ibrutinib; with emavusertib doses ranging from 100 mg to 300 mg BID. The initial data reveal encouraging efficacy, demonstrating multiple objective responses in both BTK-naive and BTK-experienced patients. Patients with PCNSL who had a history of failed BTKi therapy showed a particularly noteworthy response: 3 out of 5 evaluable PCNSL patients achieved a Complete Response (CR), with durability ranging from 0.3 - 8.9 months. These data underscore the potential of emavusertib to re-sensitize patients to BTKi therapy, marking a significant advancement in Non-HodgkinLymphoma treatment. Emavusertib is a small molecule IRAK4 inhibitor. IRAK4 plays an essential role in the toll-like receptor (TLR) and interleukin-1 receptor (IL-1R) signaling pathways, which are frequently dysregulated in patients with cancer. TLRs and the IL-1R family signal through the adaptor protein MYD88, which results in the assembly and activation of IRAK4, initiating a signaling cascade that induces cytokine and survival factor expression mediated by the NF-?B protein complex. Preclinical studies targeting IRAK1/4 in combination with FLT3 have demonstrated the ability to overcome the adaptive resistance incurred when targeting FLT3 alone. Further, emavusertib has shown anti-tumor activity across a broad range of hematologic malignancies including monotherapy activity in patient-derived xenografts and synergy with both azacitidine and venetoclax. New Risk • Nov 21
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 15% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (15% average weekly change). Earnings are forecast to decline by an average of 6.7% per year for the foreseeable future. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$65m net loss in 3 years). Shareholders have been diluted in the past year (22% increase in shares outstanding). Market cap is less than US$100m (US$43.2m market cap). Price Target Changed • Nov 04
Price target increased by 18% to US$180 Up from US$153, the current price target is an average from 2 analysts. New target price is 3,839% above last closing price of US$4.57. Stock is down 71% over the past year. The company is forecast to post a net loss per share of US$9.13 next year compared to a net loss per share of US$12.14 last year. Reported Earnings • Nov 03
Third quarter 2023 earnings: EPS and revenues exceed analyst expectations Third quarter 2023 results: US$2.13 loss per share (improved from US$2.84 loss in 3Q 2022). Revenue: US$2.83m (flat on 3Q 2022). Net loss: US$12.2m (loss narrowed 8.4% from 3Q 2022). Revenue exceeded analyst estimates by 7.9%. Earnings per share (EPS) also surpassed analyst estimates by 9.7%. Revenue is forecast to grow 25% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, earnings per share has increased by 4% per year but the company’s share price has fallen by 41% per year, which means it is significantly lagging earnings. Tillkännagivande • Oct 27
Curis, Inc. to Report Q3, 2023 Results on Nov 02, 2023 Curis, Inc. announced that they will report Q3, 2023 results at 8:00 AM, US Eastern Standard Time on Nov 02, 2023 New Risk • Aug 18
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 9.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 11% per year for the foreseeable future. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$65m net loss in 3 years). Share price has been volatile over the past 3 months (9.8% average weekly change). Shareholders have been diluted in the past year (28% increase in shares outstanding). Market cap is less than US$100m (US$78.3m market cap). Reported Earnings • Aug 04
Second quarter 2023 earnings: EPS and revenues miss analyst expectations Second quarter 2023 results: US$0.12 loss per share (improved from US$0.17 loss in 2Q 2022). Revenue: US$2.20m (down 8.2% from 2Q 2022). Net loss: US$12.0m (loss narrowed 25% from 2Q 2022). Revenue missed analyst estimates by 13%. Earnings per share (EPS) also missed analyst estimates by 2.1%. Revenue is forecast to grow 24% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has fallen by 21% per year, which means it is significantly lagging earnings. Tillkännagivande • Jul 29
Curis, Inc. to Report Q2, 2023 Results on Aug 03, 2023 Curis, Inc. announced that they will report Q2, 2023 results After-Market on Aug 03, 2023 Tillkännagivande • Jul 07
U.S. Food and Drug Administration Removes Partial Clinical Hold on Curis, Inc.'s TakeAim Leukemia Study RP2D Established At 300 Mg BID Curis, Inc. announced that the U.S. Food and Drug Administration (FDA) has removed the partial clinical hold on the TakeAim Leukemia Phase 1/2 study of emavusertib. Further, the recommended phase 2 dose (RP2D) for emavusertib as a monotherapy has been established at 300 mg BID in patients with Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndromes (MDS). On April 4, 2022, the Company announced that the FDA placed a partial clinical hold on the TakeAim Leukemia study. On August 30, 2022, the Company announced that the FDA notified Curis that it may resume enrollment of additional patients in the monotherapy dose finding phase of the TakeAim Leukemia study, so that the Company could enroll at least nine additional patients at the 200 mg BID dose level. On July 6, 2023, the Company announced the FDA had removed the partial clinical hold on the TakeAim Leukemia study and that the RP2D has been established at 300 mg BID. In the TakeAim Leukemia study, as of the March 17, 2023 data cutoff for patients dosed prior to February 9, 2023, 84 patients received emavusertib monotherapy, ranging from doses of 200 mg to 500 mg BID. Significant blast count reductions have been observed across all patient groups, regardless of dose level, mutation status, or number of prior lines of treatment. Emerging from these data are two genetically-defined subpopulations of relapsed/refractory (R/R) patients who have demonstrated compelling responses in monotherapy: AML patients with FLT3 mutation and AML patients with spliceosome mutation (U2AF1 or SF3B1 mutation) who have received <= 2 prior lines of treatment. In these subpopulations of evaluable patients (patients whose disease has been determined to be evaluable for objective response with baseline and post-treatment marrow assessments) treated with 300 mg BID, 2 of 3 patients with a FLT3 mutation achieved a CR (Complete Response), and 2 of 3 patients with spliceosome mutation achieved a CR or CRh (Complete Response with Partial Hematologic Recovery). The duration of response for these patients ranged from 5.6 to 7.0 months. 
